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Abstract: Inhaled anesthetics have been in clinical use for over 150 years and are still commonly 
used in daily practice. The initial view of inhaled anesthetics as indispensable for general anesthesia 
has evolved during the years and, currently, its general use has even been questioned. Beyond the 
traditional risks inherent to any drug in use, inhaled anesthetics are exceptionally strong greenhouse 
gases (GHG) and may pose considerable occupational risks. This emphasizes the importance of 
evaluating and considering its use in clinical practices. Despite the overwhelming scientific evidence 
of worsening climate changes, control measures are very slowly implemented. Therefore, it is the 
responsibility of all society sectors, including the health sector to maximally decrease GHG emis-
sions where possible. Within the field of anesthesia, the potential to reduce GHG emissions can be 
briefly summarized as follows: Stop or avoid the use of nitrous oxide (N2O) and desflurane, consider 
the use of total intravenous or local-regional anesthesia, invest in the development of new technol-
ogies to minimize volatile anesthetics consumption, scavenging systems, and destruction of waste 
gas. The improved and sustained awareness of the medical community regarding the climate im-
pact of inhaled anesthetics is mandatory to bring change in the current practice. 
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1. Introduction 
Inhaled anesthetics have been in clinical use since 1844 [1]. Their discovery was a 
landmark as the first form of general anesthesia. Over the years, improved inhaled anes-
thetics were developed and implemented in clinical practice, while older drugs were 
abandoned due to toxic effects [2]. Unlike other drugs in clinical use, inhaled anesthetics 
carry a specific occupational risk for the health care workers due to their volatile nature. 
Inhaled anesthetics are highly inert molecules, resulting in minimal to absent biotransfor-
mation—and thus virtually no production of toxic metabolites. This unique chemical 
property, however, also results in exceptional atmospheric stability, causing these pow-
erful greenhouse gases to have long-lasting ecological effects, requiring special attention 
from researchers, policymakers, and society in general. 
A 2019 The Lancet article from an international collaboration dedicated to studying 
climate change on health stated that, based on current indicators, climate changes are oc-
curring faster than government responses [3]. In order to revert the actual climate crisis 
scenario, new approaches are needed. Given the excessive ecological effects of volatile 
anesthetics, anesthesia bears an important responsibility here. However, an inclusive 
study reporting the (dis) advantages for the patient versus occupational risks and envi-
ronmental effects is warranted to have a well-considered analysis of the possible clinical 
impacts of any changes in anesthesia practices. Therefore, this review recounts the results 
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of the available scientific literature and interpretation of data related to the inhaled anes-
thetics from three different perspectives: 
The first perspective is the environmental effect of inhaled anesthesia, starting with 
the current climate crisis, presenting the link between climate change and health, showing 
the evidence for the role of inhaled anesthetics, and suggesting ideas for improvements. 
The second perspective is from an occupational point of view, which investigates the 
risks that exposure to inhaled anesthetics during the work journey can bring to healthcare 
workers. 
The third perspective is from the clinical side, discussing potential benefits or harm 
from using inhaled anesthetics to the patient in different clinical contexts. 
The clinical discussions presented in this review focus on evaluating the need for 
inhaled anesthetics. They do not function as a pro–con comparison between the use of 
total intravenous anesthesia (TIVA) and inhaled anesthesia, but rather briefly show the 
available evidence from different areas where inhaled anesthetics are used. 
2. Inhaled Anesthetics and the Environment 
2.1. Global Warming 
The average global temperature is rising rapidly, a phenomenon that is causing dra-
matic climate changes. The last 5 years have been the hottest since the industrial era [4]. 
Between 2030 and 2052 an average increase of 1.5 °C or higher in the global temperature 
is expected when compared with the pre-industrial levels [5]. 
The temperature of the earth depends on the balance between the radiation energy 
received and emitted by the planet. The planet receives radiation energy from the sun. A 
part of the solar radiation is directly reflected back into space, a part is absorbed by the 
atmosphere and the surfaces—land and ocean—and ultimately emitted back to space. The 
difference between the radiation received and the radiation emitted back is called radia-
tive forcing. The wavelengths of the incoming solar energy is largely between 0.1–2.0 µm, 
whereas the wavelength of the outgoing energy from the earth is in the much longer wave-
length range of infrared light [6]. Some specific gases in the atmosphere absorb the out-
going radiation within this wavelength range. The energy is subsequently converted into 
heat, which helps keep the lower layer of the atmosphere warmer. Gases with this ability 
to absorb infrared light are the so-called greenhouse gases (GHGs). The most important 
GHGs are CO2, methane (CH4), water vapor, nitrous oxide (N2O), and fluorocarbons. The 
phenomenon of trapping heat in the atmosphere is known as the greenhouse effect, which 
is a natural and necessary process that enables life on earth. However, in the last century, 
the human activity has rapidly increased the release of GHGs in the atmosphere, resulting 
in the excessive greenhouse effect. This phenomenon, called global warming, has led to 
an increase in average temperatures despite relatively small variations in the received so-
lar energy [7]. 
2.2. Climate Change, Health Impacts, and Challenges for Reducing Emission of GHG 
Considering the looming climate crisis, multiple effects on human health are ex-
pected. The World Health Organization considers climate change the greatest threat to the 
global human health [8]. The impact of climate change on health can be direct or indirect 
[9]. Directly, heat or cold waves will lead to higher morbidity and mortality, especially in 
a high-risk population such as children and elders, while floods and storms are likely to 
increase the rate of transmissible diseases. Indirectly, health problems are anticipated re-
sulting from environmental modifications such as changing patterns of disease-carrying 
vectors, similar to mosquitos or ticks, resulting in an increase in water-borne diseases ow-
ing to higher temperatures and increasing rainfall [9]. 
In 2018, The Lancet reported and summarized the direct and indirect effects of climate 
change [10]. They concluded that climate change is expected to influence the environment, 
leading to increases in cardiovascular and pulmonary disease, undernutrition, diarrhea, 
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and vector-borne disease, etc. In addition, social consequences from this scenario would 
be the loss of habitation, mass migration, and poverty and could also result in violent 
conflicts. 
The human activity is the principal trigger of the current warming of the planet. In 
1997, the Kyoto Protocol was an important step from the international community in dis-
cussing and setting limitations and targeted emission reductions. The 2015 Paris agree-
ment, which included more nations, established the goal of strengthening efforts to limit 
global warming to 2.0 °C or even a more desirable 1.5 °C. To achieve these goals, an ex-
tensive reduction in greenhouse gas emissions is necessary [10]. While the biggest changes 
need to happen at the governmental and societal levels, anesthesiologists may make a 
significant difference as individuals. 
2.3. The Carbon Footprint of the Healthcare Sector 
The healthcare system itself generates a considerable amount of GHGs, which has, 
so far, received little attention. Importantly, GHGs other than CO2 contribute particularly 
strongly to the total GHG emissions of the healthcare industry [11]. Therefore, it is im-
portant that GHG emissions coming from the healthcare sector are taken into account in 
the assessments on health and climate [10]. Pichler et al. estimated an average healthcare 
carbon footprint of 5.5% (3.3–8.1%) from the total percentage of the national footprint in 
36 countries between 2000 and 2014 [12]. Likewise, the carbon footprint of the healthcare 
sector is estimated to correspond to 8% of the total CO2 emissions in the Netherlands, and 
7% in the United States of America [12,13]. If global healthcare was considered a country, 
it would be the fifth highest with regards to GHG emissions [11]. 
2.4. Quantification of the Warming Effect of Pollutants 
A commonly used measure to quantify and compare the warming effect of each gas 
is called global warming potential (GWP). The GWP of each gas is mainly defined by its 
half-life in the atmosphere and its spectrum-specific radiation absorption capacity. Obvi-
ously, a gas that remains in the atmosphere for decades to centuries will have the ability 
to trap much more heat, compared to a gas that is eliminated within days after release. 
Second, while solar radiation mainly consists of waves in the range of visible, ultraviolet, 
and near infrared light, with wavelengths between 100 nm (UV) and 4 µm (near-IR)), the 
earth emits its heat in the range of longer wavelengths. Within the electromagnetic spec-
trum of emitted energy by the earth, most of the wavelengths are unavailable for cooling 
since natural GHGs (mainly water, CO2, and N2O) absorb virtually every photon of many 
infrared wavelengths emitted by the earth. Only small “windows” remain for certain 
wavelengths to escape to space. A gas with an absorption at the wavelengths of the “open 
windows” (white zones in Figure 1) will induce more additional heat-trapping effects 
compared with a gas with absorption at wavelengths for which the atmosphere is already 
impenetrable (grey zones in Figure 1). As such, the additional absorption by a pollutant 
is highly variable depending on its absorption spectrum. 
 
Figure 1. Atmospheric absorption bands. Modified from an image obtained from the Wikimedia 
website, available under a CC-BY-SA 3.0 license, and included in this review on this basis. 
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A previous IPCC report described the dedicated method for GWP calculations [14]. 
CO2 is used as a reference for all GWP calculations, and by definition has a GWP of 1. 
Consequently, the GWP of the other gases is quantified relative to the warming effect of 
CO2. To include the relevant time frame of heat-trapping, the time range reference is ex-
pressed, with the denotation GWP(t). The most common time periods used for the GWP 
estimates are 20, 100 or 500 years, with GWP(100) being the most common and the reference 
used in the Kyoto Protocol. For example, if a gas has a GWP(100) of 298, it means that 1 kg 
of this gas captures the same amount of heat over a period of 100 years as 298 kg of CO2. 
2.5. Contribution from Inhaled Anesthetics 
There are important differences in the global warming effects of different volatile 
anesthetics. First, depending on its specific molecular structure the atmospheric half-life 
varies from a few years to more than a century. Second, the intrinsic ability of the different 
volatiles to absorb infrared wavelengths in the atmospheric windows varies within orders 
of magnitude. Third, the amount of agent used in the inhaled gas mixture varies between 
a few percent to 70%. Notoriously, 1-h of anesthesia performed with desflurane contrib-
utes 26 times more to global warming than the equivalent anesthesia performed with 
sevoflurane. Likewise, the addition of N2O increases the global warming impact of 
sevoflurane-based anesthesia with 590% [15]. 
Whenever used in clinical conditions, virtually the total amount of gases used during 
any procedure is eventually discarded to the atmosphere [16]. In the atmosphere, the 
wavelength of infrared absorption by the inhaled anesthetics overlaps the range of the 
atmospheric window [17]. Therefore, inhaled anesthetics absorb the radiation and re-emit 
it to the earth, contributing to the global warming process. Unfortunately, the majority of 
these gases also last for years to centuries in the atmosphere, intensifying their global 
warming effect. In 1999, the global warming impact of inhaled anesthetics was estimated 
as 0.03% of the total global warming and more recently 0.6% [11,18]. As a consequence of 
increasing the use and long half-life values, global atmospheric levels of inhaled anesthet-
ics are steadily increasing [19]. Projections about the inhaled anesthetic market suggest 
that the total inhaled anesthetic volume in use, and consequently in the atmosphere will 
have increased 4.0% between 2015 and 2024 [20]. 
A clearer understanding about the environmental impact of inhaled anesthetics can 
be achieved by comparing it to the emission of CO2 during a single car trip. The use of 
inhaled anesthetics for 1 h in their commonly used concentrations of 1 MAC and a FGF of 
1 L·min−1 has the CO2 equivalency as a car trip of 6.5 km for sevoflurane, 14 km for isoflu-
rane, 95 km for nitrous oxide, and 320 km for desflurane [21]. 
Currently, the most commonly used inhaled anesthetic agents are the hydrofluoro-
carbons sevoflurane and desflurane, the chlorofluorocarbon isoflurane, and N2O. The 
Montreal Protocol, adopted to control chlorofluorocarbons, was signed in 1987. While it 
was amended in 2016 to also reduce the use of hydrofluorocarbons, owing to the medical 
relevance of inhaled anesthetics, these substances were systematically excluded [22]. 
2.5.1. Desflurane 
Desflurane is the volatile anesthetic with the highest GWP100 of 2540 and an atmos-
pheric lifetime of 14 years [23]. Worldwide, the total estimated equivalent release of total 
CO2 (tCO2) by hydrofluorocarbon anesthetics was approximately 3 million metric tons, 
with desflurane accounting for 2.5 million [19]. MacNeill et al. demonstrated the impact 
of desflurane use in clinical practice in a well-designed report, in which huge—10 fold—
disparities in GHG emissions between hospitals could largely be accounted to the use of 
desflurane in comparison with less harmful gases [24]. 
  




Sevoflurane has GWP100 of 130 and an atmospheric lifetime of 1.1 year [23]. In addi-
tion, since with sevoflurane an end-tidal value of around 2% is targeted, compared to 6% 
with desflurane, the actual amount of emitted chemicals for 1 h of anesthesia is even three 
times higher with the latter. 
2.5.3. Isoflurane 
Isoflurane has a GWP100 of 510, and an atmospheric lifetime of 3.2 years [23]. Im-
portantly, isoflurane contains a chlorine atom and consequently induces ozone destruc-
tion. Hence, it should be discouraged in favor of sevoflurane [19]. 
2.5.4. N2O 
N2O has a very weak anesthetic potency and is therefore administered in very high 
doses (60% of inhaled gas mixture versus 2% for sevoflurane). Furthermore, it is com-
monly combined with other anesthetics, as a carrier gas, since it is not potent enough to 
lead to a full anesthetic state alone. Although the concomitant use of N2O theoretically 
permits a reduction in the amount of the other inhaled anesthetic in use, N2O itself has a 
GWP100 of 298 and an atmospheric lifetime of a staggering 114 years [23]. Due to its ex-
tremely long atmospheric lifetime and the high consumption volumes, N2O becomes a 
major contributor to global warming. 
2.5.5. The Carbon Footprint of Anesthetics 
Although the impact of inhaled anesthetics is lower compared with other GHGs such 
as methane and black carbon, the current projections for an increase in the use of inhaled 
anesthetics represent a significant burden on the future greenhouse effect [25]. The GWP 
of an anesthetic is crucial in establishing its carbon footprint, but there are many other 
factors that must be considered: CO2 emissions during manufacturing, transport, delivery, 
and even during a possible destruction of each anesthetic. Therefore, the life cycle assess-
ment is the methodology used to estimate the environmental impact of all the processes 
involved from creation to destruction of a determined product [26]. Accordingly, one 
study assessed the life cycle GHG emissions of inhaled anesthetic drugs and compared it 
to propofol [27]. Desflurane showed the greatest life cycle GHG emission, 15 and 20 times 
higher compared with isoflurane and sevoflurane, respectively. Undeniably, propofol 
showed by far the lowest total GHG emission. Even when considering emissions in the 
production processes and additional waste, the GHG release of propofol is about four 
orders of magnitude lower compared with those of volatile anesthetics [27]. 
2.6. Flow Rate of Inhaled Anesthetics 
The environmental impact from inhaled anesthetics depends not only on the inherent 
characteristics of each gas but also on the amount used. To ensure adequate general anes-
thesia, the administered dose relates to the minimum alveolar concentration (MAC), 
which is 2% for sevoflurane, compared to 6% for desflurane. Although there is no globally 
accepted definition of low-flow anesthesia, conventionally a fresh gas flow (FGF) of ≤1 
L·min−1 is considered low-flow anesthesia [28]. Contemporary ventilators permit even 
much lower FGF of 0.1 L·min−1, allowing maximal gas recirculation and reducing anes-
thetic waste. In addition to the less consumption of inhaled anesthetic, resulting in re-
duced costs and environmental impact, other benefits of minimal FGF include conserva-
tion of temperature and humidity in the system [29]. An investment in modern ventilation 
systems as such may simultaneously enable environmental and financial savings and im-
proved patient safety [28]. 
  




Inhaled anesthetics represent an important part of the costs of the anesthesia depart-
ment. The costs of any procedure are dependent upon the type of anesthetic used, the 
targeted patient concentration of volatile anesthetic, and the FGF [30]. The estimated cost 
at 1 L/min for desflurane is USD 12.96, whereas for isoflurane and sevoflurane it is USD 
0.52 and 6.05, respectively [31]. In practical terms, desflurane is the most expensive in-
haled anesthetic. 
Different experiences with cost savings have already been reported. By discouraging 
the use of desflurane in favor of sevoflurane, an estimated saving of more than USD 
100,000 over 1 year was reported [30]. Similarly, in another service, after a recall from the 
manufacturer, desflurane was no longer available in the operating room unless the anes-
thesiologist requested it. With this intervention, there was an absolute reduction of 25.2% 
in the use of desflurane, an increase of 2.6% in the use of sevoflurane, and an increase of 
17.2% in the use of isoflurane. These modifications also resulted in a saving of more than 
USD 100,000 per year [32]. 
2.8. Suggestions for Mitigating the Impact of Inhaled Anesthetics on Global Warming 
A much more sustainable anesthesia practice can easily be achieved with a conscious 
decision-making process for the choice of and use of inhaled anesthesia. At the moment, 
most anesthesiologists in operating rooms are still largely unaware of the climate impact 
that they can produce or prevent. The current curriculum from specialization programs 
to form anesthesiologists, anesthesiologist assistants, and nurses hardly ever includes sci-
entific information about the environmental impact of inhaled anesthetics. Therefore, in-
creasing the awareness of healthcare professionals may represent an easy and accessible 
step towards greener practices. Likewise, (online) educational programs towards active 
professionals may be organized as part of continuing medical education. Positive experi-
ences with the education of the anesthesia team regarding the use of inhaled anesthetics 
were already reported [33]. Implementing an initial lecture on the theme, followed by a 
continuous online education, reduced the use of desflurane by 64% over a period of 3 
years, resulting in an estimated cost savings of USD 25,000 per month. Remarkably, the 
motivational factor to implement changes in clinical practice was greater when the envi-
ronmental impact rather than monetary savings was the focus [33]. 
Practical adjustments in daily clinical practice may also contribute to mitigate GHG 
emissions. Decreasing the FGF of an inhaled anesthetic is an easy and achievable approach 
that can tackle two important issues: The ecological impact of an inhaled anesthetic and 
the costs of its consumption. Furthermore, the incentive to implement closed-circuit sys-
tems is an easy strategy to dramatically reduce inhaled anesthetic waste. 
Considering the high pollutant effect of desflurane and the low clinical difference 
compared with less-polluting alternatives, it should be replaced by more eco-friendly op-
tions. Likewise, considering its high pollutant impact and particularly long atmospheric 
lifetime, N2O should be avoided as a carrier gas in clinical practice (when possible). The 
American Association of Anesthesiologists recently started a campaign encouraging hos-
pitals to reduce the use of desflurane and N2O as well as inhaled anesthetic by 50%. These 
ideas should be stimulated and applied on a global scale [34]. 
Improving and investing in the development of scavenging systems could also miti-
gate the environmental effects of inhaled anesthetics. In recent years, new scavenging sys-
tems have been proposed to adsorb any waste gases on activated carbon or zeolite for 
subsequent reuse or destruction [35]. However, the safety and usability of these new sys-
tems, as well as the cost-effectiveness, have not yet been demonstrated [36]. An important 
consideration in this context is that N2O is not captured by these systems. A recently pro-
posed technology envisions the direct destruction of inhaled anesthetics through gas-
phase photochemistry [37]. Although at this stage only results of prototype experiments 
are available, this technology would enable a convenient add-on destructor for turning 
J. Clin. Med. 2021, 10, 1306 7 of 23 
 
 
the volatile anesthetics into harmless gases, which can subsequently be eliminated 
through the existing exhaust system. In Sweden, the use of different techniques to destroy 
N2O is already practiced and has also shown a beneficial cost effect when compared to 
other ways to reduce GHG emissions [38]. 
Xenon is a noble gas, which, in most respects, is an ideal substitute for conventional 
volatile anesthetics. Contrary to the other inhaled anesthetics, xenon is not a GHG and 
does not cause environmental damage. Xenon is a trace gas in the earth’s atmosphere 
(0.0000087%) [39]. Industrial production entails fractional distillation of ambient air. 
While xenon is absolutely environmentally harmless, its production is very costly and en-
ergy-intensive and may, depending on the energy source, therefore also release consider-
able amounts of GHGs [40]. Research in new technology to reduce the energy requirement 
and cost of xenon production may open new possibilities in the future as an environmen-
tally benign volatile anesthetic. 
A simple solution to avoid the use of inhaled anesthetics is to give preference for 
TIVA. Through the life cycle assessment, the carbon footprint of intravenous anesthesia is 
four orders of magnitude smaller compared with using desflurane [27]. Alternatively, in 
procedures where general anesthesia is not required, the use of local-regional anesthesia 
is an option. 
3. Occupational Risks of Inhaled Anesthetics 
Waste anesthetic gases (WAGs) correspond to the small amount of gas that leaks 
from the system in the operating room or that is exhaled by the patient in the recovery 
unit [41]. During each procedure using inhaled anesthetics, many healthcare workers, in-
cluding anesthesiologists and nurses, are exposed to WAGs [41]. Although still uncertain, 
the effects of short or chronic exposure to WAGs can vary from headache, dizziness, and 
fatigue up to DNA damage [41]. 
3.1. Threshold of Anesthetics in the Workplace 
Health surveillance at the workplace is fundamental to prevent risks to professional 
activity. Promoting occupational health is the responsibility of employers and employees 
and it is enforced by government regulations [42]. Policies regarding the use of inhaled 
anesthetics vary among countries. The first regulations were established in the USA, in 
1977, when the National Institute for Occupational Safety and Health (NIOSH) deter-
mined a threshold of 25 ppm of nitrous oxide (N2O) measured as a time-weighted average 
(TWA) during the administration of the drug, and 2 ppm of the other volatile anesthetics 
[43]. Others have assigned a threshold of 50 ppm for N2O for an 8-h working day [2]. The 
European Union (EU) uses its own threshold values and exposure limits, which tend to 
be higher than the North American. Huge discrepancies in threshold limits remain, for 
example, isoflurane threshold levels vary from a maximum of 5 ppm in Denmark up to 
50 ppm in Spain. In the United Kingdom (UK), the maximum levels permitted per anes-
thetic in an 8-h TWA including 100 ppm for N2O, 50 ppm for isoflurane, and 10 ppm for 
halothane, but there are no defined values for sevoflurane or desflurane. In general, con-
sidering that absolute safe levels have not been scientifically established, most guidelines 
and policies regarding inhaled anesthetics are more advisory rather than mandatory [44]. 
To control the efficiency of WAG removal, WAG levels in exposure areas should be 
routinely measured. In the USA, in a survey among USA anesthesiologists, 97% of them 
reported using anesthesia machines with scavenging systems, showing a great adherence 
to the NIOSH recommendation [45]. However, not only the recommendations from coun-
tries may vary, but also access to scavenging and/or exhaustion systems. These factors can 
thereby diminish adherence and lead to the exposure of healthcare workers to WAGs [46]. 
A Brazilian study measured WAG levels in operating rooms with and without scavenging 
systems and found that, while in the latter the exposure was significantly higher, WAG 
exceeded the value of 2 ppm in both situations. 
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3.2. Prevention of Exposure to WAGs 
The WAG source includes leakage from the anesthesia machine and system, leakage 
in the breathing system, refilling of vaporizers, and exhalation by patients after the anes-
thetic procedure has ended [47]. Indoor pollution with WAGs is determined by the anes-
thesia technique in use, the anesthesia workstations, and/or lack or insufficiency of scav-
enging systems [48]. By far the worst indoor pollution occurs with open systems where 
there is no evacuation of the waste gases and no recirculation [47]. 
Another source of leakage may involve the use of a laryngeal mask or unsealed tra-
cheal intubation. The use of a laryngeal mask in the induction of anesthesia is accompa-
nied by anesthesiologists being exposed to higher levels of the inhaled anesthetic in use 
[48]. In addition, a ventilation system with turbulent flow is associated with higher expo-
sure to inhaled anesthetics compared to laminar flow [49]. Furthermore, after intravenous 
induction of anesthesia, depending on the personal preference of the treating anesthetist, 
mask ventilation with volatile anesthesia is often performed before placing the laryngeal 
mask/endotracheal tube. Ventilation usually involves a high FGF and an unsealed airway, 
which can cause considerable indoor contamination. 
Pediatric anesthesia is one of the procedures with the highest risk of exposure to in-
haled anesthetics [50]. The fast and safe characteristics of inhaled anesthetics to induce 
anesthesia, together with the advantage of promoting anesthesia without the need for nee-
dle puncture in kids, makes it a common and attractive option for pediatric anesthesia 
[51]. A national-wide survey in Belgium, revealed that the use of gas scavenging during 
induction is infrequent and it is related to the age of the patient, with systems without 
scavenging being more used in patients under 1-year-old [51]. During the maintenance of 
anesthesia, the use of a scavenging system is two-times higher compared with the induc-
tion. Likewise, the reduced use of scavenging system in pediatric anesthesia has also been 
reported in the UK [52]. However, in operating rooms equipped with modern ventilation 
and scavenging systems, even during pediatric surgery using N2O or sevoflurane sur-
geons were exposed to values of WAG within the recommended limits [53]. 
Precautionary practices in the administration of inhaled anesthetics vary between pe-
diatric and adult patients, with better prevention of exposure to WAGs during adult sur-
geries [45]. In cardiopulmonary bypass surgery, for instance, the exposure to sevoflurane 
generally did not exceed the recommended levels when adequate ventilation and scav-
enging is available [54,55]. 
Although several studies have explored WAG levels in the operating rooms, less at-
tention has been given to the post-anesthesia care unit (PACU). Investigation in the PACU 
of an American hospital confirmed that healthcare workers are exposed to WAGs above 
the suggested 2 ppm during the 1-h recovery time [56]. However, the use of an appropri-
ate mask in patients of this PACU effectively diminishes exposure to WAG [56]. In con-
trast, in a German hospital with controlled air exchange systems, only a low trace amount 
of sevoflurane was measured, with all levels under the limit of 2 ppm [57]. In a pediatric 
PACU, the recommended WAG levels were also exceeded during the working day, and 
exposure was related to the number of patients in the recovery room [58]. Even when the 
construction of the PACU was in accordance with the standards, the environmental WAG 
level was still higher than recommended. 
Currently, the interest in the use of inhaled anesthetics in the intensive care unit 
(ICU), as an alternative for patient sedation, is growing [59]. The clinical advantages in-
clude shortened wakening and extubating times [60]. There are novel devices that have 
been added to classical ICU ventilators to administer inhaled anesthetics as sedatives, and 
thus a separate anesthesia machine is not necessary [59]. The effective collection and evac-
uation of the pollution to the outside atmosphere effectively ensures that the level of in-
door contamination during the use of these new technologies remains below the recom-
mended levels [61,62]. Still, careful planning of scavenging and ventilation systems is cru-
cial to prevent excessive occupational exposure. 
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3.3. Health Risks Related to Inhaled Anesthetics Occupational Exposure 
The first report of a possible harmful effect of occupational exposure to inhaled an-
esthetics was in 1967, where surgeons and anesthetists reported headaches and fatigue 
after a working day using ether [63]. In addition, a high incidence of spontaneous abortion 
was reported in the interviewed female anesthesiologists [63]. Since then, discussions 
have commenced regarding the health safety of healthcare professionals involved with 
inhaled anesthetics. 
The potential harm of inhaled anesthetics to reproductive health became a topic of 
many epidemiologic studies in the early 1970s [64]. A paramount survey performed with 
almost 50,000 operating room workers showed an increased risk for spontaneous abor-
tion, teratogenic effects, cancer, and hepatic and renal disease in female workers [63]. Re-
markably, the same teratogenic effects were also valid for the wives of the exposed male 
workers [64]. At that time, the most commonly used inhaled anesthetics included N2O, 
halothane, and ether [47]. In the subsequent years, anesthetics such as chloroform, ether, 
and halothane have been removed due to toxicity [2]. Currently, the oldest inhaled anes-
thetic still in use is N2O. In animal models, N2O has a teratogenic effect [65]. However, in 
clinical settings, the impact of N2O and other anesthetic gases in general is less obvious. 
While the first epidemiological studies from the early seventies reported spontaneous 
abortion and teratogenic effects due to occupational exposure [63,64], a subsequent scien-
tific review rejected these conclusions based on methodological errors [66]. Even now, 
controversy remains due to conflicting results. A meta-analysis reported an association 
between inhaled anesthetics exposure in nurses and an increased risk of poor pregnancy 
outcomes [67]. On the other hand, a large survey among female doctors from the UK 
showed that anesthesiologists do not have higher rates of infertility when compared to 
other specialties that are not exposed to inhaled anesthetics [68]. 
It is important to emphasize that most of the studies on the subject were performed 
before scavenging systems were used and with inhaled anesthetics that are no longer in 
use. Therefore, the potential effects of chronic exposure to inhaled anesthetics regarding 
reproductive health might be even weaker [69]. However, based on the current literature, 
the impact of reproductive occupational and also other clinical health risks have not yet 
been proven [47,70]. 
Human biomonitoring (HBM) is an important tool to assess human exposure to ex-
ogenous substances such as chemical compounds and pollutants by measuring particular 
compounds or breakdown substances in material collected from subjects exposed to a de-
termined risk agent [71,72]. Different sources of human material can be analyzed to eval-
uate the toxicity of an agent, including blood, buccal cells, and urine. In the anesthesia 
field, HBM has already been employed to evaluate the potential risks of occupational ex-
posure to inhaled anesthetics, however, results have so far been inconsistent. There was a 
significant increase in chromosomal damage in medical staff exposed to inhaled anesthet-
ics when compared with medical staff not exposed [73]. Another study investigated DNA 
lesions in operating room personnel and there was no significant difference when com-
pared with the healthy population, except for a tendency to accumulate DNA lesions 
found only in anesthesiologists [74]. However, the authors considered the genotoxic effect 
to be very weak since there was no massive induction of DNA breaks in the exposed pop-
ulation. On the other hand, a different study demonstrated that WAGs induce sister chro-
matid changes, a phenomenon that is compared to the same genetic damage as smoking 
11–20 cigarettes per day [75]. 
A systematic review of biomonitoring studies in the operating room personnel con-
cluded that healthcare workers exposed to inhaled anesthetics are at a risk for a cumula-
tive genotoxic effect [76]. In accordance, a meta-analysis of DNA and chromosomal dam-
age based on lymphocyte assays also demonstrated that individuals exposed to inhaled 
anesthetics show more genotoxic damage when compared with non-exposed individuals 
[77]. Conversely, a high level of occupational exposure to inhaled anesthetics was associ-
ated with genotoxicity in the micronucleus assay, whereas a low level was not [78]. The 
J. Clin. Med. 2021, 10, 1306 10 of 23 
 
 
levels considered as low were within the range of the recommended threshold values 
from NIOSH, confirming its safety. In agreement, a systematic review found no evidence 
of adverse effects of inhaled anesthetics when exposure levels were kept within the rec-
ommended threshold levels [79]. 
Notably, a study that included the operating room personnel and PACU workers 
reported a similar genotoxicity risk for both exposed groups. The risks were significantly 
different than the non-exposed controls [80]. An additional study compared exfoliated 
buccal cells from anesthesiologists exposed to inhaled anesthetics for at least 2 years with 
age and sex-matched internal medicine doctors who were not exposed. The authors re-
ported genomic instability, cytotoxicity, and proliferative risks in the samples from ex-
posed individuals [80]. These findings have shown an increased risk in developing genetic 
alterations due to the occupational exposure to inhaled anesthetics [81]. 
The mechanisms involved in genotoxicity and exposure to inhaled anesthetics are 
still not clear. It is hypothesized that a multi-factorial model including genetic susceptibil-
ity, environmental exposure, and individual characteristics such as age, gender, and 
smoking factors contributes to the development of a disease that is caused by a genotoxic 
effect [82]. 
The genotoxic effects of each anesthetic were summarized in an interesting review 
[82]. All inhaled anesthetics caused genotoxic effects, except for xenon (although there 
was limited data). Investigations of intravenous anesthetics have shown no genotoxic ef-
fect from short-term use. In clinical settings, the influence of a single anesthetic is difficult 
to be studied, and the literature remains inconclusive. One factor proposed to be involved 
in the toxicity of inhaled anesthetics is oxidative stress [83]. Indeed, there was a correlation 
between N2O levels in the workspace and oxidative DNA damage, suggesting that in-
creased oxidative stress may be the link between chronic exposure to N2O and DNA dam-
age [83]. In addition, systemic inflammation was also evaluated and an increase in inter-
leukin 8 (IL-8) in healthcare workers exposed for 3 years to anesthetic gases was found 
when compared with non-exposed healthcare workers [84]. Notably, even healthcare 
workers exposed for a shorter time presented this increased IL-8 expression. Importantly, 
in this study, the isoflurane, sevoflurane, and N2O levels measured in the operating rooms 
were higher than NIOSH standards [84]. 
In summary, conflicting data with regards to the health risks of exposure to inhaled 
anesthetics limit the conclusions to define safety levels or appropriate exposure policies. 
In addition, biomonitoring studies are generally performed on a small scale and exposure 
to inhaled anesthetics is normally not distinguished per anesthetic. The current used in-
haled anesthetics such as desflurane and sevoflurane are less studied compared with oth-
ers such as halothane. However, designing and performing a large-scale study to analyze 
each inhaled anesthetic separately would be extremely difficult due to the heterogeneity 
of anesthesia protocols and the particularities of workplaces. Therefore, biomonitoring 
occupational risks due to inhaled anesthetics will probably remain an internal task for 
each service. 
3.4. Minimizing Exposure to WAGs 
Considering the potential health risks of exposure to WAGs, an obvious policy is to 
minimize this exposure in healthcare professionals. Different approaches to the protection 
of workers may be used. 
First and most obvious, avoid the use of inhaled anesthetics whenever possible and 
substitute it for other anesthetic routes (intravenous anesthesia or locoregional tech-
niques). This approach would eliminate any occupational concern related to WAGs. The 
European legislation regarding hydrofluorocarbon gases states that it should be banned 
in all situations where a less harmful alternative is possible [85]. Even though inhaled 
anesthetics are considered of medical need and granted an exception to the rule, if the 
clinical use of inhaled anesthetics would only be maintained in situations where no alter-
natives are available or where advantages of the use are expected, there would certainly 
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be a considerable reduction in general use and consequently, healthcare workers’ expo-
sure to WAGs. 
Second, installing and maintaining an appropriate scavenge and ventilation system 
in operating rooms and PACUs. Investing in better and more modern scavenging systems 
should be encouraged. In addition, protection devices such as special masks may also 
contribute to the control of WAGs. The use of ISO-Gard masks in patients during anes-
thetic recovery in the PACU effectively reduced environmental exposure in healthcare 
workers [86]. 
Third, controlling WAG levels in services where inhaled anesthetics are used should 
become routine to ensure that exposure to inhaled anesthetics is within the recommended 
limit, thereby guaranteeing a safe workplace for healthcare professionals. In addition, this 
information can augment the current knowledge regarding occupational risks and im-
prove the current recommendations and regulations. 
Fourth, improve anesthesia workers’ awareness regarding occupational risks related 
to their functions to consequently increase adherence and recognition of safety measure-
ments. A pilot study with anesthesiologists revealed a lack of knowledge in major topics 
of occupational health [87]. In a specific survey on inhaled anesthetics with anesthesiolo-
gists and nurse anesthetists, 76% of the participants related to feeling exposed to inhaled 
anesthetics, however, simple measures for the avoidance of WAGs were not being used 
[88]. 
4. Inhaled Anesthetics in the Clinical Context 
4.1. Side Effects 
Inhaled anesthetics are known to be much more associated with postoperative nau-
sea and vomiting (PONV) when compared with TIVA and therefore recognized as an in-
dependent predictor of PONV [89]. Therefore, omission of volatile anesthetics in favor of 
propofol is explicitly included in the guidelines for PONV prevention [90]. 
Malignant hyperthermia is a rare but severe condition that can occur in genetically 
susceptible patients as a reaction to volatile anesthetics [91]. Patients with malignant hy-
perthermia present clinical signs such as severe sudden hyperthermia, tachycardia, tach-
ypnea, and acidosis, etc. [92]. To prevent malignant hyperthermia, the use of the intrave-
nous anesthetic propofol is the preferred choice in patients susceptible to the condition 
[93]. 
Epileptiform electroencephalogram (EEG) patterns have been associated with the use 
of sevoflurane for anesthesia induction in both adults and pediatric populations [94]. Risk 
factors associated with this outcome include female sex, short delay to the onset of anes-
thesia and the concentration of sevoflurane in use [94,95]. 
Anesthesia and surgical procedures have been associated with cognitive disorders 
[96]. Postoperative cognitive disorder (POCD) can impact the affected patients clinically 
and socially, especially at an older age [97]. Although the causes and risks for POCD are 
not yet fully understood, the type of anesthesia used—TIVA or inhaled anesthetic—has 
been suggested to play a role and even if still controversial, the currently available data 
favor TIVA in place of inhaled anesthesia [97–101]. 
4.2. Anesthetic Conditioning 
Inhaled anesthetics are attributed cardioprotection, renal protection, and liver pro-
tection, as well as an immunomodulatory effect [102–105]. Volatile anesthetics seem to 
activate several of the intracellular effects responsible for ischemic preconditioning, where 
a short period of ischemia protects most organs, such as the heart, against a subsequent, 
more severe ischemia [106]. While in vitro studies have yielded seemingly convincing re-
sults, the clinical outcomes remain controversial [107]. 
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4.3. Cardiac Surgery 
Cardiac surgery often requires a period of cardiac ischemia, resulting in a significant 
incidence of postoperative infarction. Experimental models suggested cardioprotective ef-
fects by inhaled anesthetics, similar to ischemic preconditioning [108]. Since then, a vari-
ety of studies have investigated the postulated cardioprotective effect of volatile anesthet-
ics in experimental and clinical settings. 
In vitro studies and animal models have convincingly shown a cardioprotective ef-
fect from volatile anesthetics [109,110]. However, the translation of these positive results 
to the clinical setting remains an open question [107]. Clinical studies on cardiac surgery 
have varied from biomarker assessments evaluating the influence of volatile anesthetics 
in preventing cardiac damage (e.g., via troponin I) to those evaluating clinical outcomes 
such as cardiac events, length of stay in the hospital, and mortality when compared to the 
use of TIVA. Different studies have demonstrated the beneficial effect of inhaled anesthet-
ics with regards to biomarker levels [111]. 
For long-term outcomes, encouraging results have been published in recent years: 
Lower mortality risks for volatile anesthetics compared with TIVA [112,113]. However, 
other groups did not obtain the same results [113,114]. Further studies and meta-analysis 
also demonstrated contradictory results [115–118]. 
Finally, a recent large multicenter randomized controlled trial showed that there was 
no significant difference in 1-year mortality or adverse events between the group receiv-
ing volatile anesthetic conditioning when compared to the group with TIVA during car-
diac surgery [119]. However, specific characteristics of the study may have influenced the 
negative result such as the lack of a pre-defined protocol for anesthetic conditioning and 
the inclusion of patients subjected to on and off pump surgery. 
Consequently, after more than 30 years of extensive research, no superiority of either 
agent can be recommended. 
4.4. Non-Cardiac Surgery 
The potential cardioprotective effects of inhaled anesthetics have also been studied 
in non-cardiac surgery with a high risk of peri-operative cardiac events [120,121]. Initially, 
a systematic review and metanalysis about the cardioprotective effect of volatile anesthet-
ics in non-cardiac surgery found a lack of evidence regarding myocardial infarction and 
mortality and called for more research in the field [122]. Later studies did not show a dif-
ference in postoperative cardiac events or mortality with the use of inhalational or non-
inhalational anesthesia [114,116,123]. The first randomized controlled trial on the topic 
also concluded that there was no difference regarding cardioprotection between the use 
of volatile or intravenous anesthetics [124]. 
The first study to clinically demonstrate the cardioprotective effect of sevoflurane 
was performed in patients with coronary artery disease undergoing vascular surgery 
[125]. Although an encouraging result, this study was considered small and underpow-
ered to make conclusions favoring the use of inhaled anesthetics in non-cardiac surgery 
[126]. Recently, two different retrospective analyses also failed to show the cardioprotec-
tive effect of volatile anesthetics in non-cardiac surgery [127,128]. 
Unlike the alleged organ protective effects of volatile anesthetics, a study examined 
N2O with regards to its potentially detrimental effects. At first, the use of N2O was associ-
ated with increased long-term risk of myocardial infarction in patients undergoing non-
cardiac surgery, but the same conclusion was not valid for death or stroke [129]. Never-
theless, this study received much criticism due to its design. A second clinical trial was 
performed and there was no evidence that N2O increased the risk of cardiovascular com-
plications or death in major non-cardiac surgery [130]. This finding supported the safety 
profile of N2O [131]. Nevertheless, the use of N2O in clinical practice has dramatically de-
clined, mainly due to PONV risk and environmental considerations [132]. 
  
J. Clin. Med. 2021, 10, 1306 13 of 23 
 
 
4.5. Renal Transplantation 
A potential protective effect of volatile anesthetics has also been investigated in renal 
transplantation. In animal models, the use of volatile anesthetics had already been shown 
to be protective [133]. Therefore, in a clinical setting, it was hypothesized that the use of 
sevoflurane during a living donor renal transplantation would reduce kidney injury 
measured by specific biomarkers when compared with propofol-based anesthesia [134]. 
However, there were comparable results in both groups but a lower acute rejection rate 
in the sevoflurane group was found 2 years post-transplant [134]. This was suggested 
since the living donor transplantation might not present sufficient kidney injury to benefit 
from being “rescued” by volatile anesthetics. Likewise, in another trial comparing 
sevoflurane versus propofol anesthesia in kidney transplantation, the hemodynamic pro-
file during the surgery as well as postoperative outcomes and complications showed no 
significant differences between both groups [135]. 
4.6. Lung Surgery 
Recent evidence has also brought to light the potential use of inhaled anesthetics for 
lung protection. Unlike the conditioning effects of volatile anesthetics via attenuation of 
ischemia-reperfusion injury, the lung protection mechanism seems to be related to an im-
munomodulatory effect from volatile anesthetics. A prospective study using a large co-
hort demonstrated that the use of inhaled anesthetics is associated with a dose-dependent 
decreased risk of early postoperative respiratory complications, mortality, and hospital 
care costs in patients undergoing non-cardiac surgery [136]. Fittingly, the use of sevoflu-
rane was reportedly associated with a significant reduction in inflammatory markers and 
better clinical outcomes when compared with the use of TIVA during thoracic surgery 
with one-lung ventilation [137]. However, in a randomized clinical trial on the same topic, 
there was no difference regarding major complications when comparing the use of volatile 
anesthetics versus TIVA [104]. Although the latest results are interesting and intriguing, 
no conclusion or clinical advice can be provided on the topic based on the current scientific 
evidence [138]. 
4.7. Cancer Surgery 
For solid cancers, surgical removal of the tumor is most of the time the primary treat-
ment and best chance of a cure [139]. Paradoxically, perioperative factors such as the can-
cer surgery itself and the type of utilized anesthesia may increase the risk of cancer recur-
rence and mortality [140]. 
Following the initial experimental models demonstrating that anesthetics could in-
fluence cell proliferation and metastasis [141], many basic researchers have tried to un-
ravel the effects of volatile and intravenous anesthetics in cancer progression. Many 
showed that inhalational anesthetics were associated with direct damage DNA in lung 
cells and associated with increased risk of metastasis in preclinical models [142–145]. Like-
wise, TIVA was associated with anti-cancer properties [146]. Nevertheless, the translation 
from these results to clinical settings has still not been proven. 
Retrospective research on the topic have been controversial. Some studies could 
show a better survival associated with TIVA in cancer surgery [147–150], whereas others 
reported no influence of the anesthesia type on clinical outcomes [151–153]. Clinical trials 
are still ongoing and, therefore, a proper answer to the question is still lacking [154]. 
A speculative explanation for the conflicting results lays in the hypothesis that a ben-
eficial effect of TIVA might be related to the scale of the surgery, where patients undergo-
ing major cancer surgery would be more likely to benefit from the use of TIVA [155]. This 
emphasizes the complexity of the subject but if clinical trials prove the superiority of one 
anesthesia technique, adapting anesthetic practices would potentially be a fast and afford-
able way of improving postoperative cancer outcomes [156]. 
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4.8. Pediatric Surgery 
Inhalational anesthesia is traditionally the most commonly used technique in pediat-
ric surgery. However, advances in intravenous anesthesia over the last decades have led 
to a growing role for its use. 
Advantages of inhalational anesthetics include easy induction and no need for intra-
venous access [157]. Furthermore, inhalational anesthetics can be conveniently managed 
by the anesthetists. Other potential benefits of inhalational anesthesia, such as cardiopro-
tection in adults have not been confirmed in a pediatric population [158]. On the other 
hand, the use of TIVA has been associated with reduced complications such as lower in-
cidence of delirium, lower incidence of bronchospasm, and a more peaceful recovery 
[159–161]. Furthermore, volatile anesthesia was more associated with the risk of PONV, 
whereas different studies have shown a potential antiemetic property of propofol, which 
is currently considered in guidelines as the indicated anesthesia technique to minimize 
the risk of PONV [162–164]. 
5. Discussion and Conclusions 
Climate change is considered the biggest threat to public health in this century. The 
negative impact of inhaled anesthetics on the environment should be minimized. Differ-
ent approaches to reduce GHG emissions by anesthesiologists can be briefly summarized: 
Stop or avoid the use of N2O and desflurane, consider the use of intravenous or local-
regional anesthesia, and invest in the development of new technologies in scavenging sys-
tems. 
The occupational risks of exposure to inhaled anesthetics for healthcare professionals 
are still a matter of concern in anesthesiology. Although the most important health risks 
such as abortion were associated with inhaled anesthetics no longer in use, the concern 
related to long-term exposure is ongoing and warrants more regulatory involvement. Rec-
ommended exposure limits to the different inhaled anesthetics differ extensively among 
countries, and there is currently no specific global guideline on the topic. The available 
data on occupational exposure to inhaled anesthetics are still controversial, but potential 
genotoxic and carcinogenic effects cannot be excluded. WAG control measures should be 
implemented as a precaution. Furthermore, increasing awareness of healthcare workers 
regarding occupational risks, encouraging the reduction of the use of inhaled anesthetics, 
and investing in appropriate scavenging and ventilation systems are necessary towards a 
safe work environment. 
Although it may seem unlikely that a relatively short intervention such as anesthesia 
could impact long-term outcomes after surgery, a growing body of data suggest a consid-
erable impact of the anesthesia type. Considering the side effects of anesthesia, inhaled 
anesthetics increase the risk of PONV. Furthermore, the current literature correlates in-
haled anesthesia with POCD, favoring TIVA. In cardiac surgery, while the beneficial use 
of volatile anesthetics was convincingly shown in experimental and clinical models using 
biomarkers, trials using clinical outcomes have not confirmed their superiority. Moreover, 
in noncardiac surgery, there is no definitive evidence for a cardioprotective effect of vol-
atile anesthetics. Furthermore, a potential lung and kidney protective effect has been sug-
gested and is currently under investigation. In cancer surgery, volatile anesthetics seem 
harmful rather than beneficial, but conflicting data in both experimental and clinical stud-
ies limit any definitive conclusion. Finally, in pediatric surgery, TIVA has shown some 
clinical advantages, and it is expected that its use will grow in the future. 
The ideal decision-making process of choosing an anesthesia technique should in-
clude the three different perspectives represented in this review (Figure 2). Nevertheless, 
with the current environmental situation, a drastic reduction in the atmospheric emissions 
of inhaled anesthetics is necessary and urgent. Consequently, a new approach to the de-
cision-making process of choosing an anesthesia technique should start with the question: 
Is the use of inhaled anesthetics strictly necessary or potentially clinically better? 




Figure 2. Schematic view of the three different perspectives in choosing an anesthesia technique. 
Abbreviations: N2O: Nitrous oxide; TIVA: Total intravenous anesthesia; WAG: Waste anesthetic 
gas. 
Even though the clinical impact of TIVA or inhalational anesthesia is similar or often 
even superior for TIVA, inhalational anesthesia is still much more frequently used. In the 
United Kingdom (UK), a survey from the National Health System including all their ser-
vices showed that 92% of all surgeries are maintained with inhalational anesthesia, with 
sevoflurane being the most popular volatile anesthetic in use (58.5%) [165]. A survey with 
Australian anesthetists showed that only 18% of the respondents are frequent users of 
TIVA [166]. Possible explanations for the low use of TIVA were investigated via another 
survey, where only 16% of the respondents were considered frequent TIVA users [167]. 
From the infrequent TIVA users, 52% perceived it as an “additional effort” or justified the 
infrequent use with other reasons including “difficult for intravenous (IV) access”, “insti-
tutional preference”, “lack of real-time monitoring of propofol concentration”, and “risk 
of missing drug delivery failure” [167]. This result indicates that there are no strong rea-
sons against the use of TIVA and that using inhaled anesthetics might represent conser-
vation of old habits since it has been in use for a longer time. 
The idea of completely abandoning the use of inhaled anesthetics due to its impact 
on the environment has already been proposed [168]. The authors suggested that there is 
no absolute indication for the use of inhalational anesthesia, hence, it could be replaced 
by local-regional anesthesia or TIVA. Furthermore, challenges in using TIVA or loco-re-
gional anesthesia are mostly related to the operator confidence in performing it rather 
than to proper clinical evidence [168]. To overcome these obstacles, a recent guideline has 
been published with instructions for a safe practice of TIVA [169]. However, it is important 
to emphasize the lack of appropriate education regarding the environmental impacts and 
occupational risks of the use of inhaled anesthetics. Taken together, special attention 
should be given to the educational training in anesthesia as an opportunity to change 
practices and improve anesthesia from all perspectives. 
In conclusion, the use of inhaled anesthetics should be minimized as much as possi-
ble to reduce the carbon footprint of anesthesia and consequently protect public health. 
Still, the choice of a particular volatile anesthetic has much more impact than its elimina-
tion. Since replacing desflurane by sevoflurane already eliminates 96% of the greenhouse 
effect [27], it is essential to emphasize that when a volatile anesthetic is preferred, elimi-
nation of the use of desflurane and N2O should be encouraged more than converting to 
TIVA, as this is much easier to accomplish. When clinically indicated (strict indications or 
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potential benefits), workplace conditions should be adequate and healthcare professionals 
should avoid exposure. The use of inhaled anesthetics or TIVA seems to be comparable in 
terms of long-term clinical outcomes in different surgery types and TIVA is generally as-
sociated with less adverse effects of general anesthesia. 
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